PA8798401A1 - Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
PA8798401A1
PA8798401A1 PA20088798401A PA8798401A PA8798401A1 PA 8798401 A1 PA8798401 A1 PA 8798401A1 PA 20088798401 A PA20088798401 A PA 20088798401A PA 8798401 A PA8798401 A PA 8798401A PA 8798401 A1 PA8798401 A1 PA 8798401A1
Authority
PA
Panama
Prior art keywords
benzimidazol
carboxamida
pirrolidin
methyl
crystal form
Prior art date
Application number
PA20088798401A
Other languages
English (en)
Spanish (es)
Inventor
Kolaczkowski Lawrence
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8798401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8798401A1 publication Critical patent/PA8798401A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PA20088798401A 2007-10-12 2008-10-10 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida PA8798401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
PA8798401A1 true PA8798401A1 (es) 2009-05-15

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088798401A PA8798401A1 (es) 2007-10-12 2008-10-10 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (28)

Country Link
US (4) US8372987B2 (https=)
EP (2) EP2212327A1 (https=)
JP (4) JP2011500589A (https=)
KR (2) KR20100090769A (https=)
CN (2) CN101821270A (https=)
AU (1) AU2008310781B2 (https=)
BR (1) BRPI0816221A8 (https=)
CA (2) CA3006332A1 (https=)
CO (1) CO6280493A2 (https=)
CR (1) CR11368A (https=)
DK (1) DK2722046T3 (https=)
DO (1) DOP2010000099A (https=)
EC (1) ECSP10010150A (https=)
ES (1) ES2620299T3 (https=)
GT (1) GT201000080A (https=)
MX (1) MX350019B (https=)
MY (1) MY156691A (https=)
NZ (1) NZ583209A (https=)
PA (1) PA8798401A1 (https=)
PH (1) PH12012501636A1 (https=)
PL (1) PL2722046T3 (https=)
PT (1) PT2722046T (https=)
RU (2) RU2476434C2 (https=)
SG (1) SG185297A1 (https=)
TW (1) TWI422588B (https=)
UA (2) UA113277C2 (https=)
WO (1) WO2009049111A1 (https=)
ZA (1) ZA201002090B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) * 2016-03-09 2019-03-28 Crystal Pharmatech Co., Ltd. Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) * 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2

Also Published As

Publication number Publication date
BRPI0816221A8 (pt) 2015-09-22
EP2212327A1 (en) 2010-08-04
JP2019001811A (ja) 2019-01-10
CA3006332A1 (en) 2009-04-16
CN101821270A (zh) 2010-09-01
US20140024838A1 (en) 2014-01-23
RU2010116397A (ru) 2011-11-20
NZ583209A (en) 2012-06-29
MX2010003772A (es) 2010-04-21
CN105367554A (zh) 2016-03-02
ECSP10010150A (es) 2010-06-29
JP2011500589A (ja) 2011-01-06
SG185297A1 (en) 2012-11-29
EP2722046B1 (en) 2016-12-21
RU2012147692A (ru) 2014-05-20
PL2722046T3 (pl) 2017-06-30
US20130123317A1 (en) 2013-05-16
US9580410B2 (en) 2017-02-28
US8372987B2 (en) 2013-02-12
ZA201002090B (en) 2011-11-30
PT2722046T (pt) 2017-03-15
WO2009049111A1 (en) 2009-04-16
US8835647B2 (en) 2014-09-16
US20150148392A1 (en) 2015-05-28
GT201000080A (es) 2012-04-03
CA2696424C (en) 2018-07-10
CA2696424A1 (en) 2009-04-16
AU2008310781A1 (en) 2009-04-16
RU2476434C2 (ru) 2013-02-27
UA113277C2 (xx) 2017-01-10
CO6280493A2 (es) 2011-05-20
JP2017071618A (ja) 2017-04-13
MY156691A (en) 2016-03-15
DOP2010000099A (es) 2017-04-30
JP2014237659A (ja) 2014-12-18
UA101961C2 (xx) 2013-05-27
US20090099245A1 (en) 2009-04-16
BRPI0816221A2 (pt) 2015-06-16
TW200932747A (en) 2009-08-01
KR20100090769A (ko) 2010-08-17
EP2722046A1 (en) 2014-04-23
AU2008310781B2 (en) 2013-03-28
KR20160039312A (ko) 2016-04-08
MX350019B (es) 2016-12-09
CR11368A (es) 2010-10-25
PH12012501636A1 (en) 2015-07-10
ES2620299T3 (es) 2017-06-28
TWI422588B (zh) 2014-01-11
DK2722046T3 (en) 2017-03-20

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
IL202424A (en) Telomerase activating compounds for use in treating diseases, disorders and conditions related thereto
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201170832A1 (ru) Пуриновые соединения
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
PA8798401A1 (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.